Biotech
-
The Right Way to Address Prescription Drug Costs
[ad_1] Writing for STAT News, BIO’s President and CEO Jim Greenwood teamed up with Bay City Capital’s David Beier to…
Read More » -
NRC Health Trends Report Uncovers the Forces Shaping Healthcare Consumerism Nasdaq:NRC
[ad_1] LINCOLN, Neb., Dec. 21, 2018 (GLOBE NEWSWIRE) — NRC Health, the main supplier of in-depth buyer intelligence in healthcare,…
Read More » -
G1 tanks after placebo beats drug in cancer response rate test
[ad_1] G1 Therapeutics’ cancer drug trilaciclib has failed to beat placebo towards a number of efficacy measures in section 2.…
Read More » -
Here’s What To Look For From The Upcoming VBI Vaccines, Inc. – Ordinary Shares (NASDAQ:VBIV) Phase III Study
[ad_1] VBI Vaccines, Inc. – Ordinary Shares (NASDAQ:VBIV) simply introduced the main points of its lengthy awaited part III program…
Read More » -
4 Facts About Using Genetics in Pursuit of a More Perfect Christmas Tree
[ad_1] What will your Christmas items be positioned beneath this yr? A Fraser fir? A Douglas fir? An synthetic tree?…
Read More » -
Galectin Therapeutics Announces Extension of $10 Million Line Credit Nasdaq:GALT
NORCROSS, Ga., Dec. 20, 2018 (GLOBE NEWSWIRE) — Galectin Therapeutics Inc. (NASDAQ: GALT), the main developer of therapeutics that focus…
Read More » -
Apellis says timeline still on track for stalled eye drug
[ad_1] Apellis says will probably be capable of restart two trials of its APL-2 drug for eye illness geographic atrophy…
Read More » -
ESPR Esperion Therapeutics, Inc. Consolidation (NASDAQ:ESPR)
[ad_1] (NASDAQ:ESPR) Esperion Therapeutics Inc (NASDAQ:ESPR) Esperion Therapeutics, Inc. peaked out and closed at $48.90, manner up from about…
Read More » -
BIO Illustrates the Success of the Orphan Drug Act
[ad_1] The numbers may shock you. Approximately 7,000 uncommon ailments are identified to exist, and roughly 30 new ones are…
Read More » -
Amgen pays $50M for Molecular Partners’ preclinical Anti-cancer
Amgen is paying Molecular Partners $50 million (€44 million) upfront for world rights to preclinical anti-cancer immune cell activator MP0310.…
Read More »